Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon alfa-2b for Pre-fibrotic and Low/Intermediate-1 Risk Myelofibrosis
NCT04988815Phase 2Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Sep 2021
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ropeginterferon alfa-2b in primary myelofibrosis (PMF) and secondary myelofibrosis (SMF), sponsored by The University of Hong Kong. Primary endpoint: Clinicohematological responses at 24 months. Started Sep 2021; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
primary myelofibrosis (PMF)secondary myelofibrosis (SMF)
Beyond the preview
Go deeper on NCT04988815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988815.